Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic Leukemia
Status:
Unknown status
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
The cure rate for childhood acute lymphoblastic leukemia (ALL) has increased significantly in
recent decades and expected cure rates now exceed 85%. In recent years, Tyrosine Kinase
Inhibitor(TKI) has improved outcome of Philadelphia chromosome positive (Ph+)ALL . But in
some high risk groups, The prognosis of patients is still very bad and the relapse rate is
high. Clearly, new therapies are urgently needed to prevent and /or treat relapsed ALL.